The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•25 March 2026•

1 min read

Alumis Upgraded to Buy Following Positive Phase 3 Psoriasis Drug Data

Key Facts

1Alumis Inc. (ALMS) was upgraded to Buy following strong Phase 3 data for its psoriasis drug, envudeucitinib.

2The drug demonstrated 74% PASI 75 efficacy, comparable to Johnson & Johnson's newly approved Icotyde.

Version History

1 additional source confirmed this story

Alumis Inc. (ALMS) received a stock rating upgrade to 'Buy' following the release of strong Phase 3 clinical trial data for its psoriasis treatment, envudeucitinib. The drug demonstrated a 74% efficacy rate on the PASI 75 scale, placing it in direct competition with Johnson & Johnson’s recently approved Icotyde. Analysts highlighted the drug's potential to capture significant market share in the oral psoriasis medication space due to its competitive clinical profile. The company has outlined a regulatory roadmap, targeting a New Drug Application (NDA) submission in the second half of 2026. While the long-term timeline for commercialization remains a factor, the clinical success significantly de-risks the company's primary asset. Market participants are also looking forward to additional data readouts expected in 2026 for other potential indications of the drug.